Cure8 research brief
A blood antibody (anti-integrin αvβ6) was associated with relapse risk in UC and may help predict who stays in long-term remission, which could affect monitoring and treatment planning.
Clinicians treating ulcerative colitis; researchers studying UC biomarkers; patients interested in relapse prediction tests.
This retrospective cohort study measured serum anti-integrin αvβ6 (V6) antibody levels in patients with ulcerative colitis (UC) who were in clinical remission with at least 3 years of follow-up. Higher V6 antibody levels were associated with subsequent relapse; receiver-operating characteristic analysis showed an AUC of 0.73 for 1–3 year prediction.
The authors propose a serological response cutoff (≤11.99 U/mL) and a remission cutoff (≤4.23 U/mL). Antibody levels were relatively stable within individuals and decreased after starting molecular-targeted therapy.
Findings come from a retrospective cohort and are based on the published abstract; cutoffs need prospective validation and should not yet guide clinical decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
